Practice

Biosimilars: Issues, Challenges, and Strategy for Success

September 12th 2017

How can the US healthcare system learn from the European Union on market penetration for biosimilar products?

Research Highlights Filgrastim and Pegfilgrastim Biosimilars

September 11th 2017

By Jackie Syrop

Three posters presented on September 10, 2017, at the European Society for Medical Oncology (ESMO) 2017 meeting in Madrid, Spain, covered research on 2 proposed pegfilgrastim biosimilars and evaluated the use of filgrastim in oncology practice.

The Top 5 Biosimilars Articles for the Week of September 4

September 8th 2017

By The Center for Biosimilars Staff

The Center for Biosimilars recaps the top 5 stories in biosimilars news for the week of September 4, 2017.

Biologic Agents Are the Top Cost of Infusion Therapy for RA

September 6th 2017

By Jackie Syrop

Biologic agents represent the highest single cost associated with rheumatoid arthritis (RA) infusion care, a new analysis finds, with personnel, supplies, and overhead costs contributing substantially to overall costs.

Could Biosimilar Suffixes Stand in the Way of Pharmacovigilance?

September 6th 2017

By Kelly Davio

The FDA’s Adverse Event Reporting System, which allows healthcare professionals, patients, and others to submit reports on adverse events, contains over 8.5 million entries, a massive number complicated by the fact that any drug may be listed under an average of 16 different names.

When Will Patients Benefit From Deepening Infliximab Discounts?

September 6th 2017

By Kelly Davio

Seth D. Ginsberg, co-founder of Global Healthy Living Foundation, told The Center for Biosimilars®, “Currently the benefit of rebating and pricing of all infused drugs goes to the payers, health systems, hospitals and physicians, not the patients. Until patients participate in such savings, infused drug pricing has nothing to do with them.”

REDO Trial Will Help Answer Questions About Ultra-Low-Dose Rituximab Therapy

September 5th 2017

By Jackie Syrop

Several small studies have suggested that ultra–low-dose treatment with rituximab leads to good treatment responses in patients with rheumatoid arthritis compared with standard low-dose schedules of rituximab.

Baricitinib Outperforms Adalimumab in PROs in Phase 3 Study

September 5th 2017

By The Center for Biosimilars Staff

Newly published results of a phase 3 study of baricitinib, a once-daily oral Janus kinase inhibitor for the treatment of moderate to severe rheumatoid arthritis (RA), show that the small-molecule drug provided greater improvements in patient-reported outcomes than either placebo or the biologic adalimumab (Humira).

Developments in Biosimilar Approvals, Litigation, Payment, and Policy

September 4th 2017

By The Center for Biosimilars Staff

The past weeks have seen a number of important milestones for biosimilars, from product approvals and regulatory changes to policy updates and litigation developments.

The Top 5 Biosimilars Articles for the Week of August 28

September 1st 2017

By The Center for Biosimilars Staff

The Center for Biosimilars recaps the top 5 stories in biosimilars news for the week of August 28, 2017.